Does vaginal estrogen help overactive bladder and incontinence?
It can help, modestly. In postmenopausal women who have genitourinary syndrome of menopause (GSM) along with overactive bladder symptoms, low-dose vaginal estrogen may ease urgency, frequency, and urge-related leakage. It works best as an addition to standard overactive bladder care, not as a stand-alone cure.
The reason it comes up at all is that the two conditions overlap. The urinary symptoms of genitourinary syndrome of menopause, once called vaginal atrophy, include urgency and frequency, and those are the same symptoms that define overactive bladder. When the vaginal and urethral tissue thins after menopause, that irritation can look and feel like an overactive bladder. That overlap is why guidelines suggest checking for signs of this syndrome during an overactive bladder workup and offering local vaginal estrogen when it is present.
What the evidence actually shows
A systematic review of 44 randomized trials found that vaginal estrogen improved urge urinary incontinence with moderate-quality evidence, and improved urgency itself with only low-quality evidence. A menopause society review of the same body of work reached a similar read: moderate-quality evidence for urge incontinence, and low or very-low-quality evidence for frequency, urgency, and nocturia. A separate review of urinary incontinence in women describes the effect plainly as a modest improvement. With special bladder testing (called urodynamic testing), the 44-trial review also reported a decrease in bladder muscle (detrusor) overactivity, again on low-quality evidence. So it appears to be favorable, but the certainty is limited, and the size of the benefit is best called modest rather than dramatic.
Vaginal estrogen, not systemic estrogen
Local vaginal estrogen is the version that may help. Systemic estrogen, the kind taken as a pill or patch for whole-body menopause symptoms, is different. It has not been shown to help urinary incontinence, and it may actually make incontinence worse. One Cochrane review found that vaginal estrogen improved incontinence while systemic estrogen, whether alone or combined with a progestogen, worsened it. If the goal is calming the bladder, the topical version is probably the best first step.
Low-dose vaginal estrogen is a local treatment with minimal systemic absorption. For that reason it does not call for an added progestogen or routine endometrial monitoring simply because you are using it. Any vaginal bleeding after menopause should be evaluated.
Where it fits in overactive bladder care
Think of vaginal estrogen as an adjunct. The joint urology and urogynecology guideline frames it as something clinicians may offer to improve genitourinary symptoms in women who have both conditions, and it grades that as expert opinion rather than high-level proof. It is commonly used alongside the standard treatments for overactive bladder, such as behavioral therapy and bladder medications.
It is most worth trying when the tissue is thin and/or fragile. When a woman has atrophy symptoms and urge incontinence together, that same systematic review recommended vaginal estrogen, its strongest grade for any urinary indication.
How I approach it
I do not reach for vaginal estrogen as the first move for overactive bladder, but I often add it to first-line treatments because GSM and overactive bladder travel together so frequently. Behavioral strategies and, where appropriate, bladder medications are still the backbone. What vaginal estrogen adds is repair of the underlying tissue in a woman whose exam shows atrophy, and in that setting it can help the other treatments work better.
References
- Rahn DD, Carberry C, Sanses TV, et al. Vaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review. Obstetrics & Gynecology. 2014. doi:10.1097/AOG.0000000000000526
- Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/GME.0000000000001609
- Lukacz ES, Santiago-Lastra Y, Albo ME, et al. Urinary Incontinence in Women: A Review. JAMA. 2017. doi:10.1001/jama.2017.12137
- Kaufman MR, Ackerman AL, Amin KA, et al. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline. American Urological Association. 2025.
← Learn more about Vaginal Estrogen